The effect is consistent throughout the investigations, as evidenced by no heterogeneity (I 2 = 0.0%)
Researchers seeking a detailed catalogue of the preclinical publications underpinning these findings are directed to the Retatrutide Evidence Dossier
PubMed Beck, D.E., Sweeney, W.B., McCarter, M.D., & ipamorelin 201 Study Group
The Frontiers review notes specifically that during menopause, decreased DAO activity, combined with increased mast cell reactivity, sets the stage for new or worsening urticaria, flushing, and food sensitivities
The study looked only at storefront clinics and medical spas, deliberately excluding online telehealth, which the authors noted has received more scrutiny
Individual responses to peptide therapy may vary